Is Citius Oncology, Inc. (CTOR) overvalued? · $105.2M cap
Citius Oncology, Inc. (CTOR) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Citius Oncology, Inc. (CTOR) looks expensive on cached numbers — not a short thesis.
No cached income statement for CTOR, so there is no earnings base to call rich or cheap.
CTOR currently screens at market cap $105.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CTOR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CTOR stock page for the full model, not this heading.
Not investment advice.